Oncology
The FDA recently approved our personalized medicine for two different indications: ROS1-positive, metastatic non-small cell lung cancer and NTRK gene fusion-positive solid tumors.
The FDA recently approved our personalized medicine for two different indications: ROS1-positive, metastatic non-small cell lung cancer and NTRK gene fusion-positive solid tumors.